WST - West Pharmaceutical Services, Inc.
Close
313.63
-1.160 -0.370%
Share volume: 590,457
Last Updated: Fri 30 Aug 2024 10:00:03 PM CEST
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.87%
PREVIOUS CLOSE
CHG
CHG%
$314.79
-1.16
-0.37%
View ratios
Fiscal Date | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | 2024-06-30 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | Q2 2024 | |
Report Date | 2022-10-27 | 2023-02-21 | 2023-04-27 | 2023-07-27 | 2023-10-26 | 2024-02-20 | 2024-04-25 | 2024-07-25 | |
Assets | |||||||||
Total Assets | 3.317 B | 3.617 B | 3.724 B | 3.670 B | 3.755 B | 3.830 B | 3.602 B | 3.489 B | |
Current Assets | 1.734 B | 1.920 B | 1.937 B | 1.874 B | 1.972 B | 1.936 B | 1.693 B | 1.483 B | |
Inventories | 413.100 M | 414.800 M | 447.000 M | 449.400 M | 431.800 M | 434.700 M | 429.900 M | 419.200 M | |
Other Current Assets | 106.200 M | 103.000 M | 90.500 M | 94.100 M | 122.800 M | 135.800 M | 137.200 M | 138.200 M | |
Short Term Investments | 106.200 M | 103.000 M | 90.500 M | 94.100 M | 122.800 M | 135.800 M | 137.200 M | 138.200 M | |
Total Receivables | 485.300 M | 507.400 M | 513.400 M | 534.400 M | 519.100 M | 512.000 M | 524.000 M | 479.400 M | |
Current Cash | 729.000 M | 894.300 M | 886.300 M | 796.300 M | 898.600 M | 853.900 M | 601.800 M | 446.200 M | |
Total Non-current Assets | 1.583 B | 1.697 B | 1.786 B | 1.795 B | 1.782 B | 1.893 B | 1.909 B | 2.006 B | |
Property Plant Equipment | 1.069 B | 1.158 B | 1.215 B | 1.261 B | 1.312 B | 1.413 B | 1.449 B | 1.494 B | |
Other Assets | 53.900 M | 38.400 M | 36.700 M | 40.300 M | 38.800 M | 21.300 M | 19.000 M | 50.100 M | |
Intangible Assets | 18.100 M | 18.400 M | 17.800 M | 16.800 M | 15.700 M | 15.100 M | 13.900 M | 12.900 M | |
Goodwill | 104.000 M | 107.300 M | 107.800 M | 108.000 M | 106.800 M | 108.500 M | 107.600 M | 107.300 M | |
Liabilities and shareholders’ equity | |||||||||
Total Liabilities and shareholders’ equity | 3.317 B | 3.617 B | 3.724 B | 3.670 B | 3.755 B | 3.830 B | 3.602 B | 3.489 B | |
Total liabilities | 846.000 M | 931.900 M | 947.400 M | 922.900 M | 886.500 M | 948.500 M | 921.700 M | 912.600 M | |
Total current liabilities | 456.700 M | 519.000 M | 534.900 M | 511.600 M | 533.500 M | 671.800 M | 648.400 M | 633.700 M | |
Accounts Payable | 188.900 M | 215.400 M | 233.800 M | 218.000 M | 219.800 M | 242.400 M | 240.100 M | 211.700 M | |
Other liabilities | 69.100 M | 79.800 M | 83.000 M | 82.400 M | 83.500 M | 88.100 M | 86.800 M | 92.200 M | |
Current long term debt | 2.200 M | 2.200 M | 2.200 M | 2.200 M | 55.200 M | 134.000 M | 133.400 M | 132.900 M | |
Long term debt | 207.200 M | 206.700 M | 206.100 M | 205.600 M | 152.100 M | 72.800 M | 72.800 M | 72.900 M | |
Other liabilities | 69.100 M | 79.800 M | 83.000 M | 82.400 M | 83.500 M | 88.100 M | 86.800 M | 92.200 M | |
Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Total Shareholder equity | 2.471 B | 2.685 B | 2.776 B | 2.747 B | 2.868 B | 2.881 B | 2.681 B | 2.577 B | |
Common stock | 74.400 M | 74.400 M | 74.500 M | 74.300 M | 74.300 M | 74.100 M | 73.500 M | 73.000 M | |
Retained earnings | 2.913 B | 2.988 B | 3.114 B | 3.255 B | 3.416 B | 3.523 B | 3.624 B | 3.721 B |